HIV/AIDS Healthcare
HIV/AIDS healthcare infrastructure helps decrease risk of drug resistance
Published in AIDS Weekly, October 11th, 2004
According to scientists writing in the journal AIDS, "The emergence of drug resistance in human immunodeficiency virus type 1 (HIV-1) may limit the clinical benefits of antiretroviral therapy."
"There is no objective evidence that the risk of drug resistance is greater in resource-limited settings than in the developed world," D.R. Kuritzkes and colleagues said.
"Treatment programs will be most successful at preventing the spread of drug resistance if they provide healthcare infrastructures to maximize the effectiveness of antiretroviral therapy...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2004-10-11)
More Articles from AIDS Weekly
- HIV/AIDS Epidemiology
HIV-1 subtypes unchanged among heterosexuals in England and Wales from 1997-2000 - HIV/AIDS Therapy
HIV salvage therapy safe and effective in patients with >200 CD4+ cell counts - HIV/AIDS Therapy
Novel technique monitors safety/efficacy of HIV therapy - HIV/AIDS Therapy
Stereochemistry and regiochemistry of NNRTI profoundly affects anti-HIV activity - Human Immunodeficiency Virus
Targeting of HIV-1 RNA-DNA hybrid structures potential strategy for therapy - AIDS/HIV Therapy
Effort underway to improve the quality of HIV care in U.S. - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
